← All Casi Pharmaceuticals, INC filings

Casi Pharmaceuticals, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

CASI
Casi Pharmaceuticals, INC
SCHEDULE: Foresite Capital Divests Entire CASI Pharma Stake
Foresite Capital reports a complete divestment of its beneficial ownership in CASI Pharmaceuticals, Inc., holding 0% of ordinary shares as of December 31, 2025.
CASI
Casi Pharmaceuticals, INC
SCHEDULE: Chen Zhenfeng Discloses 11% Stake in CASI Pharma
Chen Zhenfeng has reported a beneficial ownership of 11.0% in CASI Pharmaceuticals, Inc., totaling 2,255,636 ordinary shares.
CASI
Casi Pharmaceuticals, INC
SCHEDULE: Foresite Capital Maintains 6.3% Stake in CASI Pharma
Foresite Capital Fund VI LP, Foresite Capital Management VI LLC, and James Tananbaum collectively report a 6.3% beneficial ownership in CASI Pharmaceuticals, Inc. Ordinary Shares.
CASI
Casi Pharmaceuticals, INC
SCHEDULE: Foresite Capital Discloses 5.1% Stake in CASI Pharma
Foresite Capital entities and James Tananbaum report beneficial ownership of 5.1% of CASI Pharmaceuticals, Inc.'s Ordinary Shares.
CASI
Casi Pharmaceuticals, INC
SCHEDULE: Panacea Venture Affiliates Maintain Significant Stake in CASI Pharmaceuticals
Panacea Venture Healthcare Fund II, L.P. and its related entities, including James Huang, reported continued beneficial ownership of 13.8% of CASI Pharmaceuticals, Inc.'s Ordinary Shares.